, Volume 71, Issue 2, pp 123–130


Trials, Tribulations and Termination


  1. 1.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999; 354 (9178): 602]. Lancet 1998; 352(9131): 837–53CrossRefGoogle Scholar
  2. 2.
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1998; 352 (9139): 1558]. Lancet 1998; 352(9131): 854–65CrossRefGoogle Scholar
  3. 3.
    DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173–94PubMedCrossRefGoogle Scholar
  4. 4.
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106–18PubMedCrossRefGoogle Scholar
  5. 5.
    Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385–411PubMedCrossRefGoogle Scholar
  6. 6.
    Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334(9): 574–9PubMedCrossRefGoogle Scholar
  7. 7.
    Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes 1996; 45 Suppl. 3: S45–6PubMedCrossRefGoogle Scholar
  8. 8.
    Hemmingsen B, Lund SS, Wetterslev J, et al. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 2009 Jul; 161(1): 1–9PubMedCrossRefGoogle Scholar
  9. 9.
    Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes: new agents reduce insulin resistance but need long term clinical trials. BMJ 2000; 321(7256): 252–3PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Nattrass M, Alberti KG. Biguanides. Diabetologia 1978; 14(2): 71–4PubMedCrossRefGoogle Scholar
  11. 11.
    Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11(4): 223–41PubMedCrossRefGoogle Scholar
  12. 12.
    Krentz AJ. Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study, in the metabolic syndrome: diabetes, obesity, hyperlipidemia and hypertension. In: Crepaldi GT, Avogaro AA, editors. Amsterdam: Excerpta Medica International Conference Series, 2002: 261–77Google Scholar
  13. 13.
    Johnsen SP, Monster TB, Olsen ML, et al. Risk and shortterm prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006; 13(2): 134–40PubMedCrossRefGoogle Scholar
  14. 14.
    Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547–54PubMedCrossRefGoogle Scholar
  15. 15.
    Gale EA. Diabetes in the UK: time for a reality check? Diabet Med 2010; 27(9): 973–6PubMedCrossRefGoogle Scholar
  16. 16.
    Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–89PubMedCrossRefGoogle Scholar
  17. 17.
    DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368(9541): 1096–105PubMedCrossRefGoogle Scholar
  18. 18.
    Kahn SE, Haffner SM, Heise MA, et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355(23): 2427–43PubMedCrossRefGoogle Scholar
  19. 19.
    Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298(10): 1180–8PubMedCrossRefGoogle Scholar
  20. 20.
    Nissen SE, Nicholls SJ, Wolski K, et al., PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299(13): 1561–73PubMedCrossRefGoogle Scholar
  21. 21.
    Krentz A. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes Metab Res Rev 2009; 25(2): 112–26PubMedCrossRefGoogle Scholar
  22. 22.
    Nathan DM, Buse JB, Davidson MB, et al., American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52(1): 17–30PubMedCrossRefGoogle Scholar
  23. 23.
    Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [published erratum appears in Endocr Pract 2009; 15 (7): 768–70]. Endocr Pract 2009; 15(6): 540–59PubMedCrossRefGoogle Scholar
  24. 24.
    National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents (partial update of CG66) [online]. Available from URL: http://www.nice.org.uk/CG87 [Accessed 2010 Nov 22]
  25. 25.
    Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147(8): 578–81PubMedCrossRefGoogle Scholar
  26. 26.
    Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones: what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12: 1023–35PubMedCrossRefGoogle Scholar
  27. 27.
    Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007; 357(1): 28–38PubMedCrossRefGoogle Scholar
  28. 28.
    Home PD, Pocock SJ, Beck-Nielsen H, et al., RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125–35PubMedCrossRefGoogle Scholar
  29. 29.
    BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24): 2503–15PubMedCrossRefGoogle Scholar
  30. 30.
    US FDA. Avandia (rosiglitazone): REMS — risk of cardiovascular events [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm [Accessed 2010 Dec 6]
  31. 31.
    European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true [Accessed 2010 Dec 6]
  32. 32.
    Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304(4): 411–8PubMedCrossRefGoogle Scholar
  33. 33.
    Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. Epub 2010 Jun 28Google Scholar
  34. 34.
    Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010; 363(16): 1489–91CrossRefGoogle Scholar
  35. 35.
    Blind E, Dunder K, de Graeff PA, et al. Rosiglitazone: a European regulatory perspective. Diabetologia. Epub 2010 Dec 14Google Scholar
  36. 36.
    Shah ND, Montori VM, Krumholz HM, et al. Responding to an FDA warning: geographic variation in the use of rosiglitazone. N Engl J Med 2010; 363: 2081–4PubMedCrossRefGoogle Scholar
  37. 37.
    Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294(20): 2581–6PubMedCrossRefGoogle Scholar
  38. 38.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008 Dec [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulator [Accessed 2010 Nov 12]
  39. 39.
    EMA (2008). Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003182.pdf [Accessed 2010 Dec 16]
  40. 40.
    Cohen D. Rosiglitazone: what went wrong? BMJ 2010 Sep 6; 341: c4848PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Institute for Diabetes in Older People, Bedfordshire and Hertfordshire Postgraduate Medical SchoolUniversity of Bedfordshire, Putteridge Bury CampusLutonUK

Personalised recommendations